Maria Estela Martinez-Escala1, Alba L Posligua1, Heather Wickless2, Audrey Rutherford2, Kimberly A Sable1, Belen Rubio-Gonzalez3, Xiaolong A Zhou1, Jason B Kaplan4, Barbara Pro4, Jaehyuk Choi1, Christiane Querfeld3, Steven T Rosen3, Joan Guitart5. 1. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 2. Department of Dermatology, University of Texas Southwestern, Dallas, Texas. 3. Division of Dermatology, City of Hope Comprehensive Cancer Center, Duarte, California; Beckman Research Institute, Duarte, California. 4. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois. 5. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address: j-guitart@northwestern.edu.
Abstract
BACKGROUND: Cutaneous lymphoma diagnosed after anti-tumor necrosis factor-α therapy (anti-TNF-α) has been reported in the literature, yet a clear link between both events remains elusive. OBJECTIVE: To review our experience with cutaneous lymphoma diagnosed during or after the use of anti-TNF-α therapies. METHODS: This is a multicenter retrospective study and a literature review. RESULTS: A total of 22 cases, including 20 cutaneous T-cell lymphomas (CTCLs) and 2 cutaneous B-cell lymphomas, were identified. In the CTCL group, 75% of the patients received an anti-TNF-α agent for a presumed inflammatory skin condition. Mycosis fungoides and Sézary syndrome were the most common subtypes of CTCL diagnosed. Advanced disease (stage IIB to IVA) was commonly seen at time of diagnosis and required aggressive therapy, including stem cell transplant in 3 patients; 2 patients in whom cutaneous B-cell lymphomas was diagnosed had an indolent course. A total of 31 cases were gathered from a literature search. LIMITATIONS: This is a retrospective study. CONCLUSIONS: Our findings suggest that the disease of most of the identified patients was misdiagnosed as psoriasis or eczema; therefore, a comprehensive morphologic and molecular review of skin biopsy specimens and peripheral blood samples should be considered before initiation of anti-TNF-α therapy in patients with poorly defined dermatitis or atypical presentations of psoriasis.
BACKGROUND:Cutaneous lymphoma diagnosed after anti-tumor necrosis factor-α therapy (anti-TNF-α) has been reported in the literature, yet a clear link between both events remains elusive. OBJECTIVE: To review our experience with cutaneous lymphoma diagnosed during or after the use of anti-TNF-α therapies. METHODS: This is a multicenter retrospective study and a literature review. RESULTS: A total of 22 cases, including 20 cutaneous T-cell lymphomas (CTCLs) and 2 cutaneous B-cell lymphomas, were identified. In the CTCL group, 75% of the patients received an anti-TNF-α agent for a presumed inflammatory skin condition. Mycosis fungoides and Sézary syndrome were the most common subtypes of CTCL diagnosed. Advanced disease (stage IIB to IVA) was commonly seen at time of diagnosis and required aggressive therapy, including stem cell transplant in 3 patients; 2 patients in whom cutaneous B-cell lymphomas was diagnosed had an indolent course. A total of 31 cases were gathered from a literature search. LIMITATIONS: This is a retrospective study. CONCLUSIONS: Our findings suggest that the disease of most of the identified patients was misdiagnosed as psoriasis or eczema; therefore, a comprehensive morphologic and molecular review of skin biopsy specimens and peripheral blood samples should be considered before initiation of anti-TNF-α therapy in patients with poorly defined dermatitis or atypical presentations of psoriasis.
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Joel M Gelfand; Daniel B Shin; Andrea L Neimann; Xingmei Wang; David J Margolis; Andrea B Troxel Journal: J Invest Dermatol Date: 2006-06-01 Impact factor: 8.551
Authors: Nouf Alballa; Alanoud Alyousef; Albatool Alamari; Ahmed Abdullah Alhumidi; Mohammed Ayesh Zayed; Leena Zeitouni; Fahad Mohammed Alsaif Journal: AME Case Rep Date: 2018-12-24
Authors: N A Trum; J Zain; X U Martinez; V Parekh; M Afkhami; F Abdulla; K R Carson; S T Rosen; C L Bennett; C Querfeld Journal: Br J Dermatol Date: 2021-10-20 Impact factor: 9.302
Authors: Alex M Trafford; Rosa Parisi; Martin K Rutter; Evangelos Kontopantelis; Christopher E M Griffiths; Darren M Ashcroft Journal: PLoS One Date: 2021-07-19 Impact factor: 3.240
Authors: Sara Yumeen; Fatima N Mirza; Julia M Lewis; Kacie R Carlson; Brett King; Shawn Cowper; Christopher G Bunick; Jennifer McNiff; Michael Girardi Journal: JAAD Case Rep Date: 2020-04-30